Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19

被引：39

作者：

Ghosh, Arun K. ^{[1
,2
]}

Mishevich, Jennifer L. ^{[1
,2
]}

Mesecar, Andrew ^{[1
,3
,4
]}

Mitsuya, Hiroaki ^{[5
,6
,7
]}

机构：

[1] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA

[2] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA

[3] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA

[4] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA

[5] Kumamoto Univ, Dept Hematol, Sch Med, Kumamoto 8608556, Japan

[6] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA

[7] Natl Ctr Global Hlth & Med Res Inst, Shinjuku Ku, Tokyo 1628655, Japan

来源：

CHEMMEDCHEM | 2022年 / 17卷 / 22期

基金：

美国国家卫生研究院;

关键词：

antiviral drugs; COVID-19; coronavirus; drug design; inhibitors; protein X-ray structures; SARS-CoV-2; PAPAIN-LIKE PROTEASE; SMALL-MOLECULE INHIBITORS; MAIN PROTEASE; 3C-LIKE PROTEASES; CORONAVIRUS; SARS; DISCOVERY; POTENT; DESIGN; IDENTIFICATION;

D O I：

10.1002/cmdc.202200440

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

COVID-19, caused by SARS-CoV-2 infection, continues to be a major public health crisis around the globe. Development of vaccines and the first cluster of antiviral drugs has brought promise and hope for prevention and treatment of severe coronavirus disease. However, continued development of newer, safer, and more effective antiviral drugs are critically important to combat COVID-19 and counter the looming pathogenic variants. Studies of the coronavirus life cycle revealed several important biochemical targets for drug development. In the present review, we focus on recent drug design and medicinal chemistry efforts in small molecule drug discovery, including the development of nirmatrelvir that targets viral protein synthesis and remdesivir and molnupiravir that target viral RdRp. These are recent FDA approved drugs for the treatment of COVID-19.

引用

页数：28

共 151 条

[1] The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model [J].

Abdelnabi, Rana ;

Foo, Caroline S. ;

Kaptein, Suzanne J. F. ;

Zhang, Xin ;

Do, Thuc Nguyen Dan ;

Langendries, Lana ;

Vangeel, Laura ;

Breuer, Judith ;

Pang, Juanita ;

Williams, Rachel ;

Vergote, Valentijn ;

Heylen, Elisabeth ;

Leyssen, Pieter ;

Dallmeier, Kai ;

Coelmont, Lotte ;

Chatterjee, Arnab K. ;

Mols, Raf ;

Augustijns, Patrick ;

De Jonghe, Steven ;

Jochmans, Dirk ;

Weynand, Birgit ;

Neyts, Johan .

EBIOMEDICINE, 2021, 72

[2] Potent Inhibition of SARS-CoV-2 nsp14 N7-Methyltransferase bySulfonamide-Based Bisubstrate Analogues [J].

Ahmed-Belkacem, Rostom ;

Hausdorff, Marcel ;

Delpal, Adrien ;

Sutto-Ortiz, Priscila ;

Colmant, Agathe M. G. ;

Touret, Franck ;

Ogando, Natacha S. ;

Snijder, Eric J. ;

Canard, Bruno ;

Coutard, Bruno ;

Vasseur, Jean-Jacques ;

Decroly, Etienne ;

Debart, Francoise .

JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (08) :6231-6249

[3] A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals [J].

Alugubelli, Yugendar R. ;

Geng, Zhi Zachary ;

Yang, Kai S. ;

Shaabani, Namir ;

Khatua, Kaustav ;

Ma, Xinyu R. ;

Vatansever, Erol C. ;

Cho, Chia-Chuan ;

Ma, Yuying ;

Xiao, Jing ;

Blankenship, Lauren R. ;

Yu, Ge ;

Sankaran, Banumathi ;

Li, Pingwei ;

Allen, Robert ;

Ji, Henry ;

Xu, Shiqing ;

Liu, Wenshe Ray .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240

[4] Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial [J].

Aman, Jurjan ;

Duijvelaar, Erik ;

Botros, Liza ;

Kianzad, Azar ;

Schippers, Job R. ;

Smeele, Patrick J. ;

Azhang, Sara ;

Bartelink, Imke H. ;

Bayoumy, Ahmed A. ;

Bet, Pierre M. ;

Boersma, Wim ;

Bonta, Peter, I ;

Boomars, Karin A. T. ;

Bos, Lieuwe D. J. ;

Bragt, Job J. M. H. van ;

Braunstahl, Gert-Jan ;

Celant, Lucas R. ;

Eger, Katrien A. B. ;

Geelhoed, J. J. Miranda ;

Glabbeek, Yurika L. E. van ;

Grotjohan, Hans P. ;

Hagens, Laura A. ;

Happe, Chris M. ;

Hazes, Boaz D. ;

Heunks, Leo M. A. ;

Heuvel, Michel van den ;

Hoefsloot, Wouter ;

Hoek, Rianne J. A. ;

Hoekstra, Romke ;

Hofstee, Herman M. A. ;

Juffermans, Nicole P. ;

Kemper, E. Marleen ;

Kos, Renate ;

Kunst, Peter W. A. ;

Lammers, Ariana ;

Lee, Ivo van der ;

Lee, E. Laurien van der ;

Zee, Anke-Hilse Maitland-van der ;

Asam, Pearl F. M. Mau ;

Mieras, Adinda ;

Muller, Mirte ;

Neefjes, Elisabeth C. W. ;

Nossent, Esther J. ;

Oswald, Laurien M. A. ;

Overbeek, Maria J. ;

Pamplona, Carolina C. ;

Paternotte, Nienke ;

Pronk, Niels ;

Raaf, Michiel A. de ;

Raaij, Bas F. M. van .

LANCET RESPIRATORY MEDICINE, 2021, 9 (09) :957-968

[5]

[Anonymous], PFIZ NOV COVID 19 OR

[6]

[Anonymous], 2019, CORONAVIRUS COVID 19

[7]

[Anonymous], WHO-Convened Global Study of Origins of SARS-CoV-2

[8]

[Anonymous], Chem. Eng. News

[9]

Appili Therapeutics Inc, 2021, FAV PAT MILD MOD DIS

[10] The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds [J].

Baez-Santos, Yahira M. ;

St John, Sarah E. ;

Mesecar, Andrew D. .

ANTIVIRAL RESEARCH, 2015, 115 :21-38

← 1 2 3 4 5 6 7 8 9 10 →